Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2016³â 9¿ù 23ÀÏ(±Ý) ~ 2016³â 9¿ù 24ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F] |
(08:00~17:00) |
|
34-GO0108:00~08:00 |
±è¼ö¹Ì ´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú |
The induced anti-cancer effects of Radachlorin-mediated photodynamic therapy in human endometrial adenocarcinoma cell line HEC-1-A |
35-GO0208:00~08:00 |
±è¼ö¹Ì ´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú |
Synergistic inhibition of ovarian cancer cell NIH: OVCAR-3 growth by combining a natural isothiocyanate sulforaphene with cisplatin.
|
36-GO0308:00~08:00 |
±èÀºÅà °í½ÅÀÇ´ë º¹À½º´¿ø »êºÎÀΰú |
°ñ¹Ý¿¡ ±¹ÇÑµÈ ³¼Ò¾Ï óġ¿¡¼ ´ëµ¿¸Æ ÁÖÀ§ °ñ¹Ý ÀÓÆļ± ÀýÀçÀÇ À¯¿ë¼º |
37-GO0408:00~08:00 |
±èÁö¼· ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
The utility of 2-antibody panel using MSH6 and PMS2 for screening of Lynch syndrome in endometrial cancer patients |
38-GO0508:00~08:00 |
±èÁøÈÖ °¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú |
Can human papillomavirus testing predict residual/recurrent disease in patients with positive margins after LEEP? |
39-GO0608:00~08:00 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Timing and Patterns of Recurrence in Epithelial Ovarian Cancer Patients with No Gross Residual Disease after Primary Debulking Surgery, single institution experience |
40-GO0708:00~08:00 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Impact of Lymphadenectomy on Survival after Recurrence in Patients with Advanced Ovarian Cancer without Suspected Lymph Node Metastasis |
41-GO0808:00~08:00 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pre-treatment Complete Blood Cell Counts in Epithelial Ovarian Cancer patients |
42-GO0908:00~08:00 |
¼ºÁß¿± ÇѸ²ÀÇ´ë ¼º½Éº´¿ø »êºÎÀΰú |
Anticancer effect of propranolol in ovarian cancer cells regardless of platinum sensitivity |
43-GO1008:00~08:00 |
¼ÕÁÖÇõ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Clinicopathologic factors of ovarian clear cell carcinoma in a background of endometriosis: Clues
for proper treatment and follow up intervals
|
44-GO1108:00~08:00 |
¼Û°üÈí ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization |
45-GO1208:00~08:00 |
½É¹ÎÈñ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Dynamin 2 inhibitors as novel therapeutic agents in cervical cancer cells |
46-GO1308:00~08:00 |
¿À¼Ò¶ó µ¿¾Æ´ëÇб³º´¿ø »êºÎÀΰú |
Comparison of four malignancy risk indices in the preoperative evaluation of patients with borderline ovarian tumor |
47-GO1408:00~08:00 |
À±°¡¿µ ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Autotaxin-lysophosphatidic acid-LPA receptor 1 signaling can be a prominent target for development of therapy of epithelial ovarian cancer |
48-GO1508:00~08:00 |
À±Á¤¿ø ¿¬¼¼ÀÇ´ë »êºÎÀΰú |
End-of-Life care for women with ovarian cancer in Korea |
49-GO1608:00~08:00 |
ÀÌ°Ç¿ì ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
The safety and efficacy of bleomycin, etoposide and cisplatin (BEP) chemotherapy in patients with malignant ovarian germ cell tumor |
50-GO1708:00~08:00 |
À̹ÎÈñ Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú |
Minimal deviation adenocarcinoma (Adenoma malignum) of the uterine cervix;
Clinicopathological analysis of 16 cases |
51-GO1808:00~08:00 |
ÀÌ»óÈÆ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
A pilot study of HPV genotypes and prevalence in Korean women in the specific district of Seoul |
52-GO1908:00~08:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Long-term follow-up study of adult-type ovarian granulosa cell tumor |
53-GO2008:00~08:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Clinical outcome and Adverse effects of Pegylated Liposomal Doxorubicin in Korean patient
with Ovarian cancer: the Experiences of single center. |
54-GO2108:00~08:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Patterns and utility of routine surveillance in stage III-IV endometrial cancer |
55-GO2208:00~08:00 |
ÀÌ¿µÀç ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
The prognostic factors in node-positive cervical cancer patients who underwent radical hysterectomy and pelvic lymph node dissection with or without para-aortic lymph node dissection |
56-GO2308:00~08:00 |
ÀÌ¿µÀç ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Pathologic findings at risk-reducing salpingo-oophorectomy in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers |
57-GO2408:00~08:00 |
ÀÌÀ¯°æ
|
Predictive value of p16/Ki-67 dual-stained cytology for the progression of cervical dysplasia: HPV cohort study |
58-GO2508:00~08:00 |
ÀÌÀ±°æ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Outcomes of single port access surgical staging for twenty-one endometrial cancer patients |
59-GO2608:00~08:00 |
ÀÌÁ¤À± ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
External validation of chemotherapy response scoring system for histopathologic assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high grade serous carcinoma |
60-GO2708:00~08:00 |
ÀåÀÍÁø °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Distribution of HPV genotypes in association with cytological & histological results in Korean women. |
61-GO2808:00~08:00 |
ÀåÇÏ±Õ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Prognostic factors in patients with metastatic ovary tumors: multi-center study |
62-GO2908:00~08:00 |
ÀåÇý¸® ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú |
The clinical importance of the para-aortic lymphadenectomy up to the level of the renal
vessels in Endometrial cancer and Ovarian cancer |
63-GO3008:00~08:00 |
Àü¼¼Á¤ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen |
64-GO3108:00~08:00 |
Àü¼ö¿¬ °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
G-protein-coupled estrogen receptor-30 gene single nucleoid polymorphisms in ovarian cancer |
65-GO3208:00~08:00 |
Á¤´ÙÀº ¿¬¼¼´ëÇб³ ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø »êºÎÀΰú |
Overexpression of miR-9, miR-21, miR-155, and miR-944 in Formalin-Fixed Paraffin-Embedded Cervical Cancer Tissues |
66-GO3308:00~08:00 |
Á¤¿¬ÁØ Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú |
DKK3, downregulated in epithelial invasive ovarian cancer, inhibits proliferation and invasiveness of ovarian cancer cells by regulating MMP-2, MMP-9 and ¥â-catenin |
67-GO3408:00~08:00 |
Á¤¿µ½Å ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Laparoendoscopic Single Site Surgery for Cervical Cancer: A Single Surgeon Experience |
68-GO3508:00~08:00 |
Á¤À±Áö °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Anticancer funtional mechanism of Müllerian inhibiting substance/anti-Müllerian hormone concern with ICAT by regulating Wnt signal pathway in ovarian cancer |
69-GO3608:00~08:00 |
Á¶Çö³ç ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Pseudocarcinomatous hyperplasia of the Fallopian tube mimicking Tubal cancer: Radiological and Pathological diagnostic challenge
|
70-GO3708:00~08:00 |
°øÁø°æ ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Establishment of immortalized human ovarian surface epithelial cells using the lentiviral system from Korea Gynecologic Cancer Bank |
71-GO3808:00~08:00 |
ÃÖµ¿¼® ÃÖ»ó»êºÎÀΰúÀÇ¿ø |
Symptom score change and volume reduction of uterine fibroid and adenomyosis after treatment with ultrasound guided high intensity focused ultrasound |
72-GO3908:00~08:00 |
ÃÖÀ±Áø °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
E2/E6 ratio and L1 immunoreactivity as markers for detecting HPV16 positive > CIN2 lesions and cervical squamous cell carcinomas |
73-GO4008:00~08:00 |
ÃÖÇöÁø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Development of orthotopic Patient-derived tumor xenograft models in endometrial cancer |
74-GO4108:00~08:00 |
Çѳª¿µ ¼¿ï´ëÇб³º´¿ø º´¸®°ú |
Àå¾×¼º ³¼Ò¾Ï¿¡¼ÀÇ CD47 ¹ßÇö |
75-GO4208:00~08:00 |
ÇѽÃÀº ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
FOXP1: valuable target for development of treatment of cancer stem cells in ovarian cancer. |
76-GO4308:00~08:00 |
È«ÁøÈ °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Prognostic value of the sum of metabolic tumor volume of primary tumor and lymph nodes using 18F-FDG PET/CT in patients with cervical cancer |
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2016³â 9¿ù 23ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO01-GO05 (08:20~09:10) |
ÁÂÀå : ±è¿ë¹ü(¼¿ïÀÇ´ë) |
GO0108:20~08:30 |
±âÀº¿µ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Immunocytochemistry negativity for human papillomavirus L1 capsid protein as a biomarker in atypical squamous cell of undetermined significance or low grade squamous intraepthelial lesion |
GO0208:30~08:40 |
È«¿µÈñ °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Impact of Adjuvant Hysterectomy on Prognosis in Patients with Locally Advanced Cervical
Cancer Treated with Definitive Chemoradiation: A Meta-Analysis |
GO0308:40~08:50 |
°¼º¿ì ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: a propensity score matching study |
GO0408:50~09:00 |
ÀÌÀοÁ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Uniformed Indocynine Green injection protocol; the effective factor of increasing optimal sentinel lymph node mapping rate in cervical and endometrial cancers |
GO0509:00~09:10 |
ÀÌÁöÇý °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Prediction model for para-aortic lymph node metastasis in patients with locally advanced
cervical cancer |
GO06-GO10 (09:10~10:00) |
ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë) |
GO0609:10~09:20 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Germline Mutations in Patients with Epithelial Ovarian Cancer using Gene-Panel Sequencing: Beyond BRCA 1/2 |
GO0709:20~09:30 |
À̽ÅÈ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Potential urinary biomarker panel to predict malignancy in women with pelvic masses |
GO0809:30~09:40 |
±Ç¿ëÀÏ À¯·ÎÁø»êºÎÀΰú |
Glycan Markers for Ovarian Cancer with High Sensitivity and High Specificity |
GO0909:40~09:50 |
ÀÌÁ¤¿ø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-cancer Effect of Ulipristal Acetate in Uterine Leiomyosarcoma |
GO1009:50~10:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Development of a female animal model for anatomical and functional assessment of the
pelvic autonomic nerves in women |
GO11-GO15 (10:30~11:20) |
ÁÂÀå : Çã¼ö¿µ(°¡Å縯ÀÇ´ë) |
GO1110:30~10:40 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long non-coding RNA HOXA11 antisense promotes tumor progression and predicts patient prognosis in serous ovarian cancer |
GO1210:40~10:50 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The Effect of Chemical inhibition of Lysyl-tRNA Synthase-Laminin Receptor in Ovarian Cancer |
GO1310:50~11:00 |
À±Á¤¼ö °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
The long non-coding RNAs in the epithelial recurrent ovarian cancer |
GO1411:00~11:10 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Steroid Receptor Activator modulates proliferation and invasion in the human cervical cancer |
GO1511:10~11:20 |
¼µ¿¼ö ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Selective cytotoxic effect of non-thermal micro-DBD plasma in uterine cervical cancer cells |
GO16-GO20 (11:20~12:10) |
ÁÂÀå : ÀÌÀ±¼ø(°æºÏÀÇ´ë) |
GO1611:20~11:30 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long Term Survival Analysis of Carboplatin or Cisplatin Based Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients |
GO1711:30~11:40 |
À±¹ÎÁ¤ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Dose-dense paclitaxel and carboplatin for ovarian carcinoma among Korean population: single institution experience |
GO1811:40~11:50 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Survival impact of low anterior resection in the patients with epithelial ovarian cancer grossly confined to pelvic cavity: A multicenter retrospective study |
GO1911:50~12:00 |
°ûÀ翵 ¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú |
Adjuvant treatment strategy of pathological down-staged patients after radical surgery of locally advanced cervical cancer with neoadjuvant chemotherapy |
GO2012:00~12:10 |
¿ÀÁøÁÖ ´ë±¸°¡Å縯´ëÇб³º´¿ø »êºÎÀΰú |
The cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance |
GO21-GO24 (12:10~12:50) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO2112:10~12:20 |
±Ç¹ÎÁ¤ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Rapid genetic screening experience among endometrial cancer about Lynch syndrome by
surgeon |
GO2212:20~12:30 |
À¯Áö±Ù °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Prevalence and outcome of BRCA mutation in Korean epithelial ovarian cancer women |
GO2312:30~12:40 |
ÀÓ¿µ¹Ì ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Hypermethylation of the Single-minded homolog 1 (SIM1) as a novel biomarker for cervical
cancer screening |
GO2412:40~12:50 |
ÀåÅÂ±Ô °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
Natural course of HPV positive women in Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion and association of HPV genotype : HPV cohort study |
GO25-GO27 (14:00~14:30) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO2514:00~14:10 |
±è¼ö¿µ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Investigation of physician awareness regarding treatment options for cervical intraepithelial neoplasia 1 by using a survey questionnaire |
GO2614:10~14:20 |
À̹æÇö ÇѸ²ÀÇ´ë °µ¿¼º½Éº´¿ø »êºÎÀΰú |
Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study |
GO2714:20~14:30 |
Á¤¿µ½Å ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
A sufficient number of relevant ethnic controls are needed for accurate assessment according to the ACMG standards and guidelines |
GO28-GO30 (14:30~15:00) |
ÁÂÀå : ±èÈ«¹è(ÇѸ²ÀÇ´ë) |
GO2814:30~14:40 |
ÃÖÀºÁö ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
One institute experience of Robotic Single-Site Surgery, 300 Cases
|
GO2914:40~14:50 |
¹ÚÁöÀº °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Robotic infrarenal paraaortic lymphadenectomy with single-positioning approach using da Vinci Xi system: Initial experiences and comparison with dual-positioning approach using da Vinci S system |
GO3014:50~15:00 |
ÃÖÂ÷Çö ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Usefulness of hemostatic agents for minimizing ovarian damage during laparoscopic
cystectomy for endometriosis |